ICH Q12 Examples – Pharmaceutical Product Lifecycle Management Examples – FDA Guidance
...
Influenza vaccines – Quality module
Recently, EMA (European Medical Agency) published a Guideline on Influenza Vaccines – Quality Module. Though the main focus of this EMA guideline was not QbD or PAT, one section – 4.1.1.6. Characterisation – was relevant to QTPP, CQA, CPP and hints on the details of the design space (albeit...
QbD Workshop at Biomanufacturing Summit, May 23-24, 2016 at UMass Lowell
For those implementing QbD in biologics, join us in May at University of Massachusetts. Agenda and registration are as follows: QbD Risk Assessment & Design Space Workshop: May 18-20 2016: Wednesday – Thursday, 8:00AM – 5:00PM; Friday 8:00AM – 12:00PM Biomanufacturing Summit, May 23-24, 2016 at UMass Lowell...
How to integrate Raw Material Variation into QbD Risk Assessment
It’s Not the Development Scientists’ Fault! As an R&D scientist, I experienced the pressure of tight development timelines. I wanted my verification, qualification or validation lots to pass the first time so we can meet our milestones (= and to get a positive annual performance review). To achieve this, I...
3 Tips from FDA and EMA on QbD Risk Assessment for Regulatory Submissions
Every day, I receive more than 25 emails just on Quality by Design. I’ll share these questions and answers in the future, but today, we cover the questions received by FDA and EMA. FDA and EMA share 3 tips on QbD Risk Assessment and Design Space for Regulatory Submissions....
FDA on Prefilled Syringes and Combination Products — What This Means for You
This regulation affects all of us. Most of us focus only on one of these: Drugs, Therapies, or Devices. However unexpected failures and mistakes happen more often at the interface of the three, shares Dr. Lana Shiu of CDRH at FDA. I met Dr. Lana Shiu after her presentation at...
What Matters to Patients? QTPP for Vaccines: A-Vax Case Study
Many of you asked for the QbD Risk Assessment Template for Vaccines. We are happy to announce that it is now available. CMC-Vaccines Working Group published a QbD case study: A-VAX: Applying Quality by Design to Vaccines in 2012. The QTPP-CQA-CPP/CMA template is based on this A-Vax case study....
QbD Design Space for Analytical Assay — Screening DOE [Tutorial]
I’m excited to share a Case Study on QbD Design Space for Analytical Assay — Screening DOE. Dr. HS Kim from Green Cross kindly shared his slides titled: “QbD using Design of Experiments Application for Analytical Assay.” The data of the experiment comes from Experimental Design in Biotechnology (Statistics: A Series...
QbD for Vaccines: A-Vax Control Strategy [Slides]
If you are applying QbD for Vaccines, this presentation will be helpful. Dr. Hyun Sung Kim presented a summary of A-VAX case study at KOBIA 2014. Dr. HS Kim (HS from hereon) is the Quality Director at Green Cross, Korea. I share my notes with you. As with any...